AUTHORS
Huifang Huang, PhD, Diyu Hou2, Liuhuan Wang3
AFFILIATIONS
1 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
2 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
3 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
ABSTRACT
Chemoresistance originating from the protective bone marrow niche severely limits therapeutic outcomes in acute myeloid leukemia (AML) patients, wherein senescent bone marrow stromal cells (BMSCs) establish a senescence-associated secretory phenotype (SASP) to sustain leukemic cell survival; however, the core molecular axis governing BMSCs senescence remains poorly defined. Doxycycline (DOX), a clinically approved tetracycline antibiotic, has recently been reported to exert anti-senescence effects, yet its functional target and molecular cascade within the AML stromal niche remain unknown. Deciphering this unique signaling loop is critical to develop repurposed drug strategies targeting the bone marrow microenvironment. Here, we show that DOX directly targets PGC-1α to reverse BMSCs senescence and boost AML chemosensitivity by modulating alternative splicing, breaking the vicious cycle of microenvironment-driven chemoresistance.
To dissect the mechanism by which AML cells drive BMSCs senescence, we first examined primary BMSCs from AML patients and healthy donors. AML patient-derived BMSCs exhibited robust senescence, elevated p16INK4a and p21 expression, and abundant IL-6/IL-8 secretion. Similarly, BMSCs from MLL::AF9 and AML1::ETO9a murine AML models displayed significant senescence phenotypes. Mechanistically, AML cells actively depleted BMSCs mitochondria via tunneling nanotubes (TNTs), causing net mitochondrial loss and paradoxical compensatory overactivation of PGC-1α and its downstream targets NRF1/TFAM. Notably, PPARGC1A overexpression sufficed to induce BMSCs senescence, while its knockout alleviated senescence and restored chemosensitivity, indicating that PGC-1α overactivation—rather than protecting BMSCs—drives their pathological senescence.
Given the pathogenic role of dysregulated PGC-1α signaling in BMSCs senescence, we next evaluated the therapeutic potential of DOX in vitro. In AML–BMSCs co-culture systems, DOX treatment suppressed SASP factor expression and secretion of BMSCs, blocked mitochondrial transfer, reduced the expression of PGC-1α downstream NRF1/TFAM, and synergistically enhanced the cytotoxicity of cytarabine and daunorubicin against AML cells. Molecular docking, molecular dynamics simulation and biolayer interferometry (BLI) validated that DOX directly binds the C-terminal RRM domain of PGC-1α with the critical residue R740. Integrative RNA-Seq and RIP-Seq analyses of DOX-treated BMSCs uncovered widespread transcriptional and splicing alterations dominated by exon skipping. We identified 605 overlapping PGC-1α-bound genes (accounting for 72.5% of DOX-modulated splicing genes), which are functionally enriched in mitochondrial homeostasis, RNA splicing, and cellular senescence pathways. Collectively, DOX disrupts the binding interplay between PGC-1α and target mRNAs, impairs PGC-1α-dependent splicing regulation, suppresses the transcriptional activation of its downstream targets NRF1/TFAM, and thereby remodels transcriptional networks associated with mitochondrial function and stromal senescence.
For in vivo intervention, we constructed a CD105-modified BMSCs-derived biomimetic nanovesicle carrier (αCD105-mNVs/LP@DOX) with bone marrow homing capacity. In both MLL::AF9 and AML1::ETO9a AML mice, nanoformulated DOX combined with cytarabine drastically reduced senescent BMSCs, lowered intramedullary SASP levels, alleviated leukemic burden and prolonged overall survival without obvious systemic toxicity, whereas free DOX monotherapy showed limited anti-leukemic efficacy.
Collectively, our work first delineates a pathological cascade: AML cells hijack BMSCs mitochondria via TNTs to trigger compensatory PGC-1α hyperactivation, which disrupts mitochondrial homeostasis and drives BMSCs senescence to build a chemoprotective niche. We subsequently introduce DOX as a repurposed therapeutic candidate capable of reversing stromal senescence, and define its precise molecular mechanism—DOX directly targets the R740 residue of PGC-1α to disrupt transcription-splicing coupling and correct abnormal splicing of mitochondrial biogenesis genes. Combined with CD105-functionalized biomimetic nanovesicles, DOX achieves safe and potent synergistic anti-leukemic effects with standard chemotherapy. Our findings uncover a novel mitochondrial-PGC-1α senescence axis mediating AML microenvironmental drug resistance and provide a translational repurposed drug nanotherapy strategy for AML treatment.
DISCLOSURES
Diyu Hou: No relevant conflicts of interest to declare.